Cargando…

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives

Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Reverdy, Thibaut, Sajous, Christophe, Péron, Julien, Glehen, Olivier, Bakrin, Naoual, Gertych, Witold, Lopez, Jonathan, You, Benoit, Freyer, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564452/
https://www.ncbi.nlm.nih.gov/pubmed/32854393
http://dx.doi.org/10.3390/cancers12092414
_version_ 1783595718184796160
author Reverdy, Thibaut
Sajous, Christophe
Péron, Julien
Glehen, Olivier
Bakrin, Naoual
Gertych, Witold
Lopez, Jonathan
You, Benoit
Freyer, Gilles
author_facet Reverdy, Thibaut
Sajous, Christophe
Péron, Julien
Glehen, Olivier
Bakrin, Naoual
Gertych, Witold
Lopez, Jonathan
You, Benoit
Freyer, Gilles
author_sort Reverdy, Thibaut
collection PubMed
description Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date.
format Online
Article
Text
id pubmed-7564452
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75644522020-10-26 Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives Reverdy, Thibaut Sajous, Christophe Péron, Julien Glehen, Olivier Bakrin, Naoual Gertych, Witold Lopez, Jonathan You, Benoit Freyer, Gilles Cancers (Basel) Review Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date. MDPI 2020-08-25 /pmc/articles/PMC7564452/ /pubmed/32854393 http://dx.doi.org/10.3390/cancers12092414 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reverdy, Thibaut
Sajous, Christophe
Péron, Julien
Glehen, Olivier
Bakrin, Naoual
Gertych, Witold
Lopez, Jonathan
You, Benoit
Freyer, Gilles
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title_full Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title_fullStr Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title_full_unstemmed Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title_short Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
title_sort front-line maintenance therapy in advanced ovarian cancer—current advances and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564452/
https://www.ncbi.nlm.nih.gov/pubmed/32854393
http://dx.doi.org/10.3390/cancers12092414
work_keys_str_mv AT reverdythibaut frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT sajouschristophe frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT peronjulien frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT glehenolivier frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT bakrinnaoual frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT gertychwitold frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT lopezjonathan frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT youbenoit frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives
AT freyergilles frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives